E2F1-dependent oncogenic addiction of melanoma cells to MDM2

Oncogene

Volumn 31, Issue 7, 2012, Pages 828-841

  Verhaegen, M ^a   Checinska, A ^b   Riblett, M B ^a   Wang, S ^a,c   Soengas, M S ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Structural Biology and Biocomputing Programme   (Spain)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

MDM 2 inhibitors; melanoma; oncogene dependency; senescence

Indexed keywords

BORTEZOMIB; DOXORUBICIN; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR E2F1; UBIQUITIN PROTEIN LIGASE E3;

ANIMAL CELL; ARTICLE; CELL AGING; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DISEASE MARKER; DNA DAMAGE; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIVISION; CELL LINE, TUMOR; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; E2F1 TRANSCRIPTION FACTOR; G2 PHASE; HUMANS; IMIDAZOLES; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MELANOCYTES; MELANOMA; MICE; MICE, NUDE; PIPERAZINES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; RNA INTERFERENCE; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE;

EID: 84857116411     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.277     Document Type: Article

References (50)

1. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. (2007). Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 26: 3473-3481. (Pubitemid 46816754)
2. Avery-Kiejda KA, Zhang XD, Adams LJ, Scott RJ, Vojtesek B, Lane DP et al. (2008). Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res 14: 1659-1668. (Pubitemid 351469449)
3. Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L. (2001). Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol 21: 2144-2153. (Pubitemid 32479635)
4. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K et al. (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870. (Pubitemid 40558993)
5. Bennett DC. (2008). How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 21: 27-38. (Pubitemid 351421467)
6. Campanero MR, Flemington EK. (1997). Regulation of E2F through ubiquitin-proteasome-dependent degradation: stabilization by the pRB tumor suppressor protein. Proc Natl Acad Sci USA 94: 2221-2226. (Pubitemid 27136855)
7. Castresana JS, Rubio MP, Vazquez JJ, Idoate M, Sober AJ, Seizinger BR et al. (1993). Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer 55: 562-565. (Pubitemid 23328938)
8. Denoyelle C, Abou-Rjaily G, Bezrookove V, VerhaegenM, Johnson TM, Fullen DR et al. (2006). Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 8: 1053-1063. (Pubitemid 44473600)
9. Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari Jr AW et al. (2005). Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 65: 6294-6304. (Pubitemid 40994415)
10. Fu W, Ma Q, Chen L, Li P, Zhang M, Ramamoorthy S et al. (2009). MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J Biol Chem 284: 13987-14000.
11. Gray-Schopfer V, Wellbrock C, Marais R. (2007). Melanoma biology and new targeted therapy. Nature 445: 851-857.
12. Ha L, Ichikawa T, Anver M, Dickins R, Lowe S, Sharpless NE et al. (2007). ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci USA 104: 10968-10973. (Pubitemid 47175210)
13. Hoek KS. (2007). DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res 20: 466-484. (Pubitemid 47568833)
14. Hofmann F, Martelli F, Livingston DM, Wang Z. (1996). The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev 10: 2949-2959. (Pubitemid 26412522)
15. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. (2006). MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 281: 33030-33035. (Pubitemid 46036685)
16. Huang B, Deo D, Xia M, Vassilev LT. (2009). Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells. Mol Cancer Res 7: 1497-1509.
17. Jemal A, Siegel R, Xu J, Ward E. (2010). Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
18. Kass EM, Poyurovsky MV, Zhu Y, Prives C. (2009). Mdm2 and PCAF increase Chk2 ubiquitination and degradation independently of their intrinsic E3 ligase activities. Cell Cycle 8: 430-437.
19. Korotchkina LG, Demidenko ZN, Gudkov AV, Blagosklonny MV. (2009). Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A. Cell Cycle 8: 3777-3781.
20. Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, Appella E et al. (2008). Nutlin-3a activates p53 to both downregulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 68: 3193-3203.
21. Long J, Parkin B, Ouillette P, Bixby D, Shedden K, Erba H et al. (2010). Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood 116: 71-80.
22. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM et al. (2005). BRAFE600-associated senescencelike cell cycle arrest of human naevi. Nature 436: 720-724. (Pubitemid 41117276)
23. Moran DM, Maki CG. (2010). Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells. Mol Cancer Ther 9: 895-905.
24. Murga M, Bunting S, Montana MF, Soria R, Mulero F, Canamero M et al. (2009). A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat Genet 41: 891-898.
25. Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, Fernandez Y et al. (2007). Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci USA 104: 19488-19493.
26. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD et al. (2005). BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 15: 249-254. (Pubitemid 40205706)
27. Polager S, Ginsberg D. (2009). p53 and E2f: partners in life and death. Nat Rev Cancer 9: 738-748.
28. Polsky D, Cordon-Cardo C. (2003). Oncogenes in melanoma. Oncogene 22: 3087-3091. (Pubitemid 36713760)
29. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. (2004). Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23: 2934-2949. (Pubitemid 38638854)
30. Prieur A, Peeper DS. (2008). Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol 20: 150-155.
31. Ryan KM, Phillips AC, Vousden KH. (2001). Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13: 332-337. (Pubitemid 32429498)
32. Satyamoorthy K, Chehab NH, Waterman MJ, Lien MC, El-Deiry WS, Herlyn M et al. (2000). Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ 11: 467-474.
33. Sdek P, Ying H, Chang DL, Qiu W, Zheng H, Touitou R et al. (2005). MDM2 promotes proteasome-dependent ubiquitinindependent degradation of retinoblastoma protein. Mol Cell 20: 699-708. (Pubitemid 41740692)
34. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S et al. (2008). Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 105: 3933-3938. (Pubitemid 351723502)
35. Shangary S,Wang S. (2009). Small-molecule inhibitors of theMDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49: 223-241.
36. Shen H, Moran DM, Maki CG. (2008). Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res 68: 8260-8268.
37. Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS et al. (2007). An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res 67: 209-217. (Pubitemid 46142777)
38. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X et al. (2001). Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409: 207-211. (Pubitemid 32144287)
39. Soengas MS, Lowe SW. (2003). Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151. (Pubitemid 36713766)
40. Terzian T, Torchia EC, Dai D, Robinson SE, Murao K, Stiegmann RA et al. (2010). p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res 23: 781-794.
41. Vassilev LT. (2007). MDM2 inhibitors for cancer therapy. Trends Mol Med 13: 23-31. (Pubitemid 46027725)
42. Vazquez A, Bond EE, Levine AJ, Bond GL. (2008). The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7: 979-987.
43. Verhaegen M, Bauer JA, Martin de la Vega C, Wang G, Wolter KG, Brenner JC et al. (2006). A novel BH3 mimetic reveals a mitogenactivated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 66: 11348-11359. (Pubitemid 46009966)
44. Verma R, Rigatti MJ, Belinsky GS, Godman CA, Giardina C. (2010). DNA damage response to the Mdm2 inhibitor nutlin-3. Biochem Pharmacol 79: 565-574.
45. Vousden KH, Prives C. (2009). Blinded by the light: the growing complexity of p53. Cell 137: 413-431.
46. Wade M, Wang YV, Wahl GM. (2010). The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 20: 299-309.
47. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR et al. (1995). Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698.
48. Yang G, Zhang G, Pittelkow MR, Ramoni M, Tsao H. (2006). Expression profiling of UVB response in melanocytes identifies a set of p53-target genes. J Invest Dermatol 126: 2490-2506. (Pubitemid 44582271)
49. Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. (2004). MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem 279: 16000-16006. (Pubitemid 38509289)
50. Zhu Y, Poyurovsky MV, Li Y, Biderman L, Stahl J, Jacq X et al. (2009). Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol Cell 35: 316-326.